MICAL3

Across TCGA pan-cancer cohorts, MICAL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MICAL3 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MICAL3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MICAL3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where MICAL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.794	0.439	.010	23	view →
HNSC	OS	Quartile	IV	0.637	0.949	.005	13	view →
LUAD	OS	Quartile	II,III,IV	0.286	1.000	.004	12	view →
GBM	OS	Median	All	0.244	0.520	.010	4	view →
PDAC	DFS	Median	All	0.407	0.217	.021	2	view →
LSCC	DFS	Median	All	0.965	0.906	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MICAL3–CCRCC (OS)

Open the CCRCC breakdown →